摘要
目的 比较喹硫平与帕利哌酮治疗精神分裂症的疗效和不良反应.方法 将80例精神分裂症患者随机分为喹硫平组和帕利哌酮组,每组各40例.两组患者分别治疗10周.治疗前后分别用阳性与阴性症状量表（PANSS）和不良反应量表（TESS）评定两组患者的疗效和不良反应发生情况.结果 喹硫平组有效率92.5%,显效率80.0%,帕利哌酮组有效率97.5%,显效率87.5%.两组疗效比较,差异无统计学意义（P〉0.05）.喹硫平组嗜睡、头昏发生率明显高于帕利哌酮组,帕利哌酮组锥体外系不良反应、体重增加率高于喹硫平组,差异均有统计学差异.结论 帕利哌酮对精神分裂症阴性症状疗效和喹硫平相当,较少引起嗜睡、头昏症状.
Objective To compare the efficacy and safety of quetiapine and paliperidone - ER in the treatment of schizophrenia. Methods 80 patients with schizophrenia were randomly divided into quetiapine group and paliperidone - ER group, 40 cases in each group. Two groups were treated for 10 weeks. The efficacy and adverse events were assessed by positive and negative syndrome scale（PANSS） and side effects scale （TESS）before and after treatment. Results The efficacy rate of quetiapine group was 92. 5 % , and the excellence rate 80. 0% , the efficacy rate of paliperidone - ER was 97. 5% , and the excellence rate was 87.5%. There was no significant difference between both groups（ P 〉 0.05 ）. The rate of drowsiness and dizziness in the quetiapine group was significantly higher than paliperidone - ER group（ P 〉 0. 05 ）. The rate of extrapyramidal side effects（EPS）and weight increase in the paliperidone -ER group was significantly higher than quetiapine group. Conclusion Paliperidone - ER and quetiapine have similar effect the treatment of schizophrenia. It shows a favorable safety profile with few drowsiness and dizziness comparing with quetiapine.
出处
《中外医学研究》
2010年第14期3-4,共2页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
喹硫平
帕利哌酮
精神分裂症
Quetiapine
Paliperidone - ER
Schizophrenia
